CAPR at a glance
CAPRICOR THERAPEUTICS, INC. (CAPR, SEC CIK 1133869) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on August 24, 2026 and Form 4 insider filings as recently as June 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CAPRICOR THERAPEUTICS, INC. (CAPR) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $105.0 million. Diluted EPS was -$2.26.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding CAPRICOR THERAPEUTICS, INC. (CAPR) shares worth $404.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bergmann Anthony on June 25, 2026 of 24,100 shares at $30.38 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $404.7M · +0 vs prior quarter
- Latest 8-K
- Aug 24, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: development and manufacturing of cell-based therapies and exosome technologies, focus on Deramiocel for commercial and clinical use
- New emphasis on potential vaccine candidates using exosome technologies with unique manufacturing and regulatory challenges highlighted
- Strategic focus on scaling manufacturing capacity including addition of 22,000 sq ft expansion to San Diego GMP facility ahead of potential commercial launch
- Quantitative manufacturing milestone: completed San Diego facility with FDA pre-license inspection, received acceptable responses to Form 483 observations, lease at Cedars-Sinai expiring July 2026
- Noteworthy risks this year: detailed impact of May 2025 U.S. MFN drug pricing initiatives and CMS GENEROUS, GLOBE, and GUARD models on future product revenues and federal reimbursement
Risk Factors
- Regulatory risk: FDA Complete Response Letter in July 2025 for Deramiocel BLA, requiring additional Phase 3 HOPE-3 trial data, new PDUFA date August 22, 2026
- Geopolitical/macro risk: Exposure to U.S. public health policy through NIH/NIAID collaboration on StealthX™ vaccine under Project NextGen initiative
- Operational risk: Dependence on qualified donated human hearts as source material for CDCs in Deramiocel manufacturing scale-up
- Competitive risk: Potential market disruption from alternative DMD therapies, including gene editing and exon skipping technologies by competitors like Sarepta Therapeutics
- Financial risk: Reliance on equity financings with $318.1M cash (2025 year end) but net loss increased to $105.0M in 2025, risking dilution or funding gaps for further development
Management Discussion & Analysis
- No profitability, margin, or segment performance metrics mentioned
- Forward-looking statements referenced but without specific management outlook or guidance
AI summary of the CAPR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial products approved
- Net loss $40.7M vs $25.9M YoY; no margin figures disclosed
- Deramiocel R&D $13.1M, up 33% YoY; exosome research $0.5M, down 55%
- Cash, equivalents and marketable securities $237.9M at June 30, 2026
- PDUFA date August 22, 2026; planned amendment may extend FDA action date
Risk Factors
- Deramiocel approvability risk triggered by FDA committee’s 3–9 negative effectiveness vote on July 29, 2026
- Amended BLA risk increased by potential complete response letter or additional testing requirements
- NS arbitration risk following withdrawn injunction motion, with proceedings expected this fall
- Commercialization risk from no prior FDA-approved product or large-scale marketing experience
- Liquidity risk from continued net losses and need for additional capital to fund trials and development programs
AI summary of the CAPR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA PDUFA action date extended to November 22, 2026 from August 22, 2026
- Three-month delay reflects FDA classification of Deramiocel BLA amendment as major
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing Capricor’s reported financial details
Item EX-99.1: Item EX-99.1
- Deramiocel BLA remains under FDA review, preserving approval potential despite a non-binding 3–9 advisory committee vote against cardiomyopathy efficacy
- HOPE-3 primary endpoint achieved statistical significance in upper-limb function at p=0.029, supporting the company’s regulatory case
Item 8.01: Other Events
- FDA advisory panel voted 3–9 against sufficient Deramiocel efficacy evidence in DMD cardiomyopathy
- Non-binding recommendation creates significant approval risk for Capricor’s lead therapy
Item EX-99.1: Item EX-99.1
- FDA advisory committee voted 3–9 against evidence supporting Deramiocel effectiveness for DMD cardiomyopathy
- Non-binding vote creates meaningful approval risk ahead of August 22, 2026 PDUFA action date
AI summaries of CAPR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CAPR
Don't miss the next CAPR filing
- Alerts as it files. A push when CAPR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CAPR, by share count.
- Ask anything. An AI agent that reads every CAPR filing and answers with sources.
CAPR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bergmann Anthony | Sell | Jun 25, 2026 | 24,100 | $30.38 |
| Krasney Karen | M | Jun 25, 2026 | 24,100 | $3.18 |
| Krasney Karen | Sell | Jun 25, 2026 | 24,100 | $30.38 |
| Krasney Karen | M | Jun 25, 2026 | 24,100 | - |
| Bergmann Anthony | M | Jun 25, 2026 | 24,100 | $3.18 |
| Bergmann Anthony | M | Jun 25, 2026 | 24,100 | - |
| Bergmann Anthony | Sell | Jun 24, 2026 | 400 | $30.00 |
| Bergmann Anthony | M | Jun 24, 2026 | 400 | $3.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $22.3M | $0 |
| Operating Income | - | -$42.6M | -$108.1M |
| Net Income | -$22.3M | -$40.5M | -$105.0M |
| Op. Margin | - | -191.1% | - |
| Net Margin | - | -181.7% | - |
| Balance Sheet | |||
| Total Assets | - | $170.5M | $355.9M |
| Equity | $22.6M | $145.5M | $305.8M |
| ROE | -98.6% | -27.8% | -34.4% |
| Per Share | |||
| EPS | $-0.83 | $-1.15 | $-2.26 |
| Cash Flow | |||
| Operating CF | - | -$40.0M | -$69.8M |
| CapEx | $1.3M | $1.2M | $2.9M |
Source: XBRL data in CAPRICOR THERAPEUTICS, INC. (CAPR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CAPR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $404.7M |
| Q1 2026 | 25 | $390.4M |
| Q4 2025 | 23 | $359.0M |
| Q3 2025 | 22 | $74.1M |
| Q2 2025 | 21 | $93.5M |
| Q1 2025 | 18 | $68.5M |
| Q4 2024 | 13 | $82.7M |
| Q3 2024 | 10 | $20.6M |
- State Street Corp+1.22M (+56%)
- BlackRock+723.2K (+21%)
- Goldman Sachs Group+666.2K (+73%)
- FMR LLC (Fidelity)+365.1K (+47%)
- Citadel Advisors LLC+275.2K (+51%)
- Bank of America Corp−164.2K (-40%)
- Invesco Ltd−155.8K (-84%)
- Millennium Management−122.4K (-34%)
- Prudential Financial−15.7K (-64%)
- AQR Capital Management−1.1K (-11%)
- D.E. Shaw & Co+123.7K
- Two Sigma Investments−30.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 157 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CAPR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Sep 14, 2026 | - | - | |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| SC 13G | Aug 19, 2026 | - | - | |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| SC 13G | Aug 3, 2026 | - | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CAPR SEC filings: frequently asked questions
Which institutions hold CAPR stock?
As of June 30, 2026, the largest CAPRICOR THERAPEUTICS, INC. (CAPR) holders among the 13F filers tracked by SignalX were BlackRock ($99.8 million), State Street Corp ($81.8 million), Vanguard Capital Management LLC ($55.3 million), Goldman Sachs Group ($38.0 million), FMR LLC (Fidelity) ($27.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CAPR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CAPRICOR THERAPEUTICS, INC. (CAPR) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $105.0 million. Diluted EPS was -$2.26. The figures come from the XBRL data in the 10-K.
What are the main risks in CAPR's latest 10-K?
In the 10-K filed March 17, 2026, CAPRICOR THERAPEUTICS, INC. (CAPR) flagged: Regulatory risk: FDA Complete Response Letter in July 2025 for Deramiocel BLA, requiring additional Phase 3 HOPE-3 trial data, new PDUFA date August 22, 2026. Geopolitical/macro risk: Exposure to U.S. public health policy through NIH/NIAID collaboration on StealthX™ vaccine under Project NextGen initiative. (AI summary of the Risk Factors section.)
What did CAPR report in its latest 8-K?
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K on August 24, 2026 reporting Item 8.01 (Other Events). FDA PDUFA action date extended to November 22, 2026 from August 22, 2026.
What are the latest CAPR SEC filings?
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on August 24, 2026 and a Form 4 insider filing on June 29, 2026.
What is CAPR's SEC CIK number?
CAPRICOR THERAPEUTICS, INC. (CAPR)'s SEC Central Index Key (CIK) is 1133869. EDGAR lists every CAPR filing under that number.
Ask anything about CAPR
The research agent reads CAPR's filings, financials, insider trades and 13F holders, then answers with sources.